BR112022012064A2 - Formulação de distribuição de fármaco intravenosa, frasco compreendendo a mesma e método de tratamento de um sujeito acometido por ou em risco de desenvolver um distúrbio tromboembólico - Google Patents
Formulação de distribuição de fármaco intravenosa, frasco compreendendo a mesma e método de tratamento de um sujeito acometido por ou em risco de desenvolver um distúrbio tromboembólicoInfo
- Publication number
- BR112022012064A2 BR112022012064A2 BR112022012064A BR112022012064A BR112022012064A2 BR 112022012064 A2 BR112022012064 A2 BR 112022012064A2 BR 112022012064 A BR112022012064 A BR 112022012064A BR 112022012064 A BR112022012064 A BR 112022012064A BR 112022012064 A2 BR112022012064 A2 BR 112022012064A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- same
- vial
- developing
- risk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951887P | 2019-12-20 | 2019-12-20 | |
| PCT/US2020/066151 WO2021127525A1 (en) | 2019-12-20 | 2020-12-18 | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012064A2 true BR112022012064A2 (pt) | 2022-08-30 |
Family
ID=76478578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012064A BR112022012064A2 (pt) | 2019-12-20 | 2020-12-18 | Formulação de distribuição de fármaco intravenosa, frasco compreendendo a mesma e método de tratamento de um sujeito acometido por ou em risco de desenvolver um distúrbio tromboembólico |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230071973A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4076511A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023507795A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220119090A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115003325A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022012064A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3161118A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL293367A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021127525A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12703762B2 (en) | 2018-12-18 | 2026-08-11 | Novartis Ag | Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof |
| WO2023092062A1 (en) * | 2021-11-18 | 2023-05-25 | Anthos Therapeutics, Inc. | Dosing regimens of factor xi/xia antibodies |
| EP4461749A4 (en) * | 2022-01-05 | 2025-03-26 | Shanghai Mabgen Biotech Ltd. | Pharmaceutical composition containing anti-FXI/FXIA antibodies and use thereof |
| TW202405022A (zh) * | 2022-06-24 | 2024-02-01 | 美商安瑟斯治療公司 | 與抗因子xi/因子xia抗體之組合療法 |
| DE102022116219A1 (de) * | 2022-06-29 | 2024-01-04 | St. Jude Medical, Cardiology Division, Inc. | Kandidatenscreening für eine Zieltherapie |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200738261A (en) * | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
| WO2008039761A2 (en) * | 2006-09-25 | 2008-04-03 | Medimmune, Llc. | Stabilized antibody formulations and uses thereof |
| JP2010531898A (ja) * | 2007-06-28 | 2010-09-30 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | 鼻および眼へのコルチコステロイド水溶液送達 |
| LT2953969T (lt) * | 2013-02-08 | 2019-12-10 | Novartis Ag | Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui |
| JOP20160131B1 (ar) * | 2015-06-26 | 2022-03-14 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| EP3337517A4 (en) * | 2015-08-20 | 2019-04-17 | Abbvie Stemcentrx LLC | ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE |
| KR102616666B1 (ko) * | 2016-12-23 | 2023-12-27 | 노파르티스 아게 | 인자 xi 항체 및 사용 방법 |
| CN118320078A (zh) * | 2016-12-23 | 2024-07-12 | 诺华股份有限公司 | 采用抗因子XI/XIa抗体治疗的方法 |
| PT3570882T (pt) * | 2017-01-19 | 2022-01-11 | Bayer Pharma AG | Nova formulação estável para anticorpos fxia |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| EP3713965A1 (en) * | 2017-11-22 | 2020-09-30 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| WO2023092062A1 (en) * | 2021-11-18 | 2023-05-25 | Anthos Therapeutics, Inc. | Dosing regimens of factor xi/xia antibodies |
-
2020
- 2020-12-18 JP JP2022538201A patent/JP2023507795A/ja active Pending
- 2020-12-18 WO PCT/US2020/066151 patent/WO2021127525A1/en not_active Ceased
- 2020-12-18 CN CN202080093971.9A patent/CN115003325A/zh active Pending
- 2020-12-18 US US17/785,660 patent/US20230071973A1/en active Pending
- 2020-12-18 KR KR1020227024670A patent/KR20220119090A/ko active Pending
- 2020-12-18 CA CA3161118A patent/CA3161118A1/en active Pending
- 2020-12-18 IL IL293367A patent/IL293367A/en unknown
- 2020-12-18 EP EP20903182.2A patent/EP4076511A4/en active Pending
- 2020-12-18 BR BR112022012064A patent/BR112022012064A2/pt unknown
-
2025
- 2025-11-28 JP JP2025207453A patent/JP2026048712A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023507795A (ja) | 2023-02-27 |
| IL293367A (en) | 2022-07-01 |
| KR20220119090A (ko) | 2022-08-26 |
| EP4076511A4 (en) | 2024-02-14 |
| US20230071973A1 (en) | 2023-03-09 |
| WO2021127525A1 (en) | 2021-06-24 |
| EP4076511A1 (en) | 2022-10-26 |
| CN115003325A (zh) | 2022-09-02 |
| CA3161118A1 (en) | 2021-06-24 |
| JP2026048712A (ja) | 2026-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Horn et al. | Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057) | |
| Genovese et al. | Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate | |
| BR112014016672A8 (pt) | compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo | |
| JOP20200116B1 (ar) | طرق لعلاج أو الوقاية من الصداع النصفي | |
| BR112023000270A2 (pt) | Composto, composição farmacêutica, e, peptídeo | |
| Blumenthal et al. | A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors | |
| BR112022011998A2 (pt) | Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas | |
| EP3895717A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER WITH WEISSELLA CIBARIA WIKIM28 AS AN ACTIVE SUBSTANCE | |
| BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| BR112018003316A2 (pt) | compostos e métodos para entrega transmembrana de moléculas | |
| SI2691112T1 (en) | STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH | |
| EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
| Su et al. | Osteopontin promotes oncostatin M production in human osteoblasts: implication of rheumatoid arthritis therapy | |
| CO2021008665A2 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
| BR112018011607A2 (pt) | composto, composição farmacêutica, métodos para tratamento de um distúrbio relacionado ao estrogênio e de um câncer, para fabricação de um medicamento para uso terapêutico no tratamento de um distúrbio e para prevenção de um distúrbio relacionado ao estrogênio, uso de um composto ou de uma composição farmacêutica, e, processo para preparação de um produto farmacêutico. | |
| BR112022018847A2 (pt) | Anticorpos, ácido nucleico, célula hospedeira, conjugados, composição farmacêutica, dispositivo de entrega de ação prolongada para entrega ocular, método para tratar um distúrbio e uso do anticorpo | |
| Diezi et al. | Toxic and drug-induced peripheral neuropathies: updates on causes, mechanisms and management | |
| de Lima et al. | Aerobic exercise, but not metformin, prevents reduction of muscular performance by AMPk activation in mice on doxorubicin chemotherapy | |
| EP3498279A4 (en) | PHARMACEUTICAL COMPOSITION WITH AMODIAQUIN AND ANTIDIABETIC MEDICINAL PRODUCT AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING DIABETES | |
| D’Agostino et al. | Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis | |
| CR20220322A (es) | Formulaciones de anticuerpos anti-pd-l1 | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| BR112017012337A2 (pt) | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. | |
| Ji et al. | Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma |